Search

Displaying results 8271 - 8280 of 8695 in total
  1. Drug

    Banoxantrone

    go.drugbank.com/drugs/DB04975
    Investigational

    Banoxantrone is a highly selective bioreductive drug that is activated in, and is preferentially toxic to, hypoxic cells in tumours. It has been shown to work synergistically with fractionated radiation to significantly delay growth of t...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A1 Substrates
  2. Drug

    R1626

    go.drugbank.com/drugs/DB05060
    Experimental

    R1626 is one of a new class of hepatitis C therapies called polymerase inhibitors. It achieves significant reductions in viral load in chronic hepatitis C patients infected with the difficult to treat genotype 1 virus. R1626 is very effe...

  3. Drug

    BTA9881

    go.drugbank.com/drugs/DB05226
    Investigational

    BTA9881 is a respiratory syncytial virus (RSV) antiviral drug developed by the Australian company Biota Holdings. It is currently in phase I trials.

  4. Drug

    Glesatinib

    go.drugbank.com/drugs/DB06302
    Investigational

  5. Drug

    Onalespib

    go.drugbank.com/drugs/DB06306
    Investigational

  6. Drug

    Avasimibe

    go.drugbank.com/drugs/DB06442
    Experimental

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP3A Inducers
  7. Drug

    Levovirin

    go.drugbank.com/drugs/DB06523
    Experimental

  8. Drug

    Diprenorphine

    go.drugbank.com/drugs/DB01548
    IllicitInvestigationalVet approved

    A narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine. [PubChem]

  9. Drug

    PDPSC18

    go.drugbank.com/drugs/DB05167
    Experimental

    PDPSC18 is therapeutic DNA vaccine designed to fight chronic infections with the Hepatitis B virus, entering phase I clinical trials.

  10. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation. It is being developed by Am...